Envestnet Asset Management Inc. Acquires 11,029 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Envestnet Asset Management Inc. lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 18.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,909 shares of the biotechnology company's stock after acquiring an additional 11,029 shares during the period. Envestnet Asset Management Inc. owned 0.16% of United Therapeutics worth $22,167,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Cerity Partners LLC lifted its holdings in shares of United Therapeutics by 30.4% during the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock worth $4,098,000 after acquiring an additional 2,702 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in United Therapeutics by 11.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock worth $1,129,000 after purchasing an additional 376 shares in the last quarter. Korea Investment CORP increased its position in United Therapeutics by 6.2% during the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after purchasing an additional 2,300 shares in the last quarter. Concurrent Investment Advisors LLC acquired a new stake in United Therapeutics during the 1st quarter worth approximately $227,000. Finally, Nepsis Inc. increased its position in United Therapeutics by 6.7% during the 1st quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock worth $18,057,000 after purchasing an additional 3,653 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the sale, the director directly owned 19,384 shares in the company, valued at $5,613,606.40. The trade was a 13.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Nilda Mesa sold 645 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director owned 4,883 shares of the company's stock, valued at approximately $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,681 shares of company stock valued at $22,140,089 over the last quarter. Insiders own 10.30% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on UTHR shares. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. UBS Group dropped their target price on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research report on Monday, June 30th. Cantor Fitzgerald started coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price objective for the company. JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Finally, Morgan Stanley lowered their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $383.08.

United Therapeutics Price Performance

UTHR traded down $2.30 during trading hours on Friday, hitting $295.03. 24,685 shares of the stock were exchanged, compared to its average volume of 441,255. The stock has a 50-day simple moving average of $300.61 and a 200-day simple moving average of $318.55. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82. The stock has a market cap of $13.31 billion, a price-to-earnings ratio of 11.77, a price-to-earnings-growth ratio of 6.52 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period last year, the business posted $6.17 earnings per share. Sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.